In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

"ESMO 2024: Keytruda is key to first-line treatment of HER2+ mGEJ adenocarcinoma" was originally created and published by ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda, the world’s best-selling drug, in non-small ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...